Anzeige
Meldung des Tages: Chinas mineralische Vormachtstellung: Die Verwundbarkeit der Lieferkette, die Washington nicht länger ignorieren kann

Bio-Techne News

Aktie
WKN:  A12ENG ISIN:  US09073M1045 US-Symbol:  TECH Branche:  Biotechnologie Land:  USA
44,63 €
+0,1 €
+0,22%
13:13:28 Uhr
Depot/Watchlist
Marktkapitalisierung *
7,89 Mrd. €
Streubesitz
-
KGV
109,47
Dividende
0,29 EUR
Dividendenrendite
0,57%
Nachhaltigkeits-Score
55 %
Index-Zuordnung
S&P 500

Bio-Techne News

16.04.26 - PR Newswire
Bio-Techne Introduces Streamlined Brand Architecture to Help Customers Navigate Solutions Faster and With Greater Clarity
Bio-​Techne Introduces Streamlined Brand Architecture to Help Customers Navigate Solutions Faster and With Greater Clarity PR Newswire
16.04.26 - PR Newswire
Bio-Techne Introduces Streamlined Brand Architecture to Help Customers Navigate Solutions Faster and With Greater Clarity
Bio-​Techne Introduces Streamlined Brand Architecture to Help Customers Navigate Solutions Faster and With Greater Clarity PR Newswire
14.04.26 - PR Newswire
Bio-Techne to Host Conference Call on May 6, 2026, to Announce Third Quarter Fiscal 2026 Financial Results
Bio-​Techne to Host Conference Call on May 6, 2026, to Announce Third Quarter Fiscal 2026 Financial Results PR Newswire
25.03.26 - PR Newswire
Bio-Techne Advances Spatial Biology with Modular Expansion of COMET™ Suite
Bio-​Techne Advances Spatial Biology with Modular Expansion of COMET™ Suite PR Newswire
24.02.26 - PR Newswire
Bio-Techne to Present at Upcoming Investor Conferences
Bio-​Techne to Present at Upcoming Investor Conferences PR Newswire
16.02.26 - PR Newswire
Bio-Techne's Ella Platform Achieves CE-IVD Marking Expanding Access to Rapid, Cartridge‑Based Immunoassays for European Clinical Laboratories
Bio-​Techne's Ella Platform Achieves CE-IVD Marking Expanding Access to Rapid, Cartridge‑Based Immunoassays for European Clinical Laboratories PR Newswire
11.02.26 - PR Newswire
Bio-Techne Announces Changes to its Leadership Team
Bio-​Techne Announces Changes to its Leadership Team PR Newswire
04.02.26 - PR Newswire
Bio-Techne Releases Second Quarter Fiscal 2026 Results
Bio-​Techne Releases Second Quarter Fiscal 2026 Results PR Newswire
04.02.26 - PR Newswire
Bio-Techne Declares Dividend
Bio-​Techne Declares Dividend PR Newswire
02.02.26 - PR Newswire
Bio-Techne Expands 3D Stem Cell and Organoid Culture Portfolio with a Fully Defined Synthetic Alternative
Bio-​Techne Expands 3D Stem Cell and Organoid Culture Portfolio with a Fully Defined Synthetic Alternative PR Newswire
28.01.26 - PR Newswire
Bio-Techne Launches Simple Plex Ultra-Sensitive Assays on Ella Platform to Enable Femtogram-Level Detection of Neurological Biomarkers
Bio-​Techne Launches Simple Plex Ultra-​Sensitive Assays on Ella Platform to Enable Femtogram-​Level Detection of Neurological Biomarkers PR Newswire
20.01.26 - PR Newswire
Bio-Techne to Host Conference Call on February 4, 2026, to Announce Second Quarter Fiscal 2026 Financial Results
Bio-​Techne to Host Conference Call on February 4, 2026, to Announce Second Quarter Fiscal 2026 Financial Results PR Newswire
23.12.25 - PR Newswire
Bio-Techne to Present at the 2026 J.P. Morgan Healthcare Conference
Bio-​Techne to Present at the 2026 J.P. Morgan Healthcare Conference PR Newswire
11.12.25 - PR Newswire
Bio-Techne Partners with the Wyss Center Geneva to Advance Automated 3D Multiomics Technology and Accelerate Spatial Biology
Bio-​Techne Partners with the Wyss Center Geneva to Advance Automated 3D Multiomics Technology and Accelerate Spatial Biology PR Newswire
09.12.25 - PR Newswire
Bio-Techne Launches the Enhanced Leo™ System Delivering Advanced Multiplexing and High-Throughput Protein Analysis
Bio-​Techne Launches the Enhanced Leo™ System Delivering Advanced Multiplexing and High-​Throughput Protein Analysis PR Newswire
25.11.25 - PR Newswire
Bio-Techne to Present at Upcoming Investor Conferences
Bio-​Techne to Present at Upcoming Investor Conferences PR Newswire
18.11.25 - PR Newswire
Bio-Techne Licenses AI-Designed NovoBody™ Duo Molecules from Monod Bio to Expand Recombinant Protein Portfolio
Bio-​Techne Licenses AI-​Designed NovoBody™ Duo Molecules from Monod Bio to Expand Recombinant Protein Portfolio PR Newswire
06.11.25 - PR Newswire
Bio-Techne to Present at Upcoming Investor Conferences
Bio-​Techne to Present at Upcoming Investor Conferences PR Newswire
05.11.25 - PR Newswire
BIO-TECHNE DECLARES DIVIDEND
BIO-​TECHNE DECLARES DIVIDEND PR Newswire
05.11.25 - PR Newswire
Bio-Techne Releases First Quarter Fiscal 2026 Results
Bio-​Techne Releases First Quarter Fiscal 2026 Results PR Newswire

Newssuche

Videos

newspaper
20.04.26 +2,79%
Technical Trading: GBP Long im Trend
GBP/USD Long Typ: Open End Turbo WKN: VV7A4S Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »